CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, we announce that on February 15, 2017, KEW, Inc., a
privately-held molecular diagnostics company located in Cambridge, MA,
USA and Denka, Co., Ltd. , a commercial manufacturing company of
chemical and life science products, located in Tokyo, Japan, officially
entered into a joint venture, Denka-KEW Genomics LLC (“DKGX”), for the
purposes of providing comprehensive genomic profiling to cancer patients
in Japan and guiding therapeutic decisions based on individual patient
tumor profiles.

“In October, 2015, KEW and Denka announced a strategic collaboration to
establish the feasibility of using CANCERPLEX in Japanese patients. Our
recent publication in Genome Medicine (2016) is the culmination of these
efforts and serves as the basis for our establishing DKGX,” said Raju
Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics and Professor
of Medicine at Harvard Medical School and co-founder of KEW, Inc.

“The formation of DKGX represents a key milestone toward helping cancer
patients in Japan. KEW is honored to partner with Denka in this
important mission,” said Tuan Ha-Ngoc, Executive Chairman, KEW, Inc.

In the first half of 2017, DKGX will open a commercial clinical
comprehensive genomic profiling laboratory in Machida City, Tokyo. Under
terms of the agreement, KEW will license its CANCERPLEX® sequencing
platform to DKGX. Additional terms of the agreement are not disclosed at
this time.

About CANCERPLEX®

CANCERPLEX® is a comprehensive genomic profiling platform for
sequencing over 400 cancer-related genes, providing treatment decision
support for cancer patients based on a patient’s tumor genomic profile.
Using industry-leading sequencing approaches and robust data analytics,
a sample acceptance rate of >95% and a rapid turn-around time of 7-10
business days, CANCERPLEX® provides therapeutic options to >90% cancer
patients profiled.

About Denka-KEW Genomics

Name

Denka-KEW Genomics

Directory

Head Office

Nihonbashi Mitsui Tower, 1-1, Nihonbashi-Muromachi

2-chome, Chuo-ku,Tokyo 103-8338, JAPAN

Laboratory

5-1, Asahi-machi 3-chome, Machida-shi, Tokyo 194-8560, JAPAN

Paid-in Capital

10 million JPY

Capital contribution ratio

Denka 55% KEW 45%

Business Launch

April 2017

About KEW, Inc.

KEW, Inc. is a privately-held comprehensive genomic profiling company
with headquarters in Cambridge, MA, USA., dedicated to revolutionizing
cancer care by providing therapeutic options based on an individual
patient’s tumor genomic profile. CANCERPLEX® is KEW’s flagship clinical
product family for sequencing and identifying applicable targeted
therapies and clinical trials.

About Denka, Co. Ltd.

Denka Co. Ltd., is a public manufacturing and distribution company
for a variety of chemical products, including organic and inorganic
materials, polymers, electronic materials and pharmaceuticals,
contributing to the quality of life and development of society for 100
years through innovations in technology. Focusing on healthcare business
sector as a key growth area, Denka is establishing its fifth business
division, "Life Innovation", to accelerate its growth.